|
|
Article: MURR enters into holmium-166 agreement.
- Article from:
- Biotech Business Week
- Article date:
- April 19, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 APR 19 - (NewsRx.com & NewsRx.net) -- NeoRx Corp. (NERX), a cancer-therapeutics development company, announced it has executed an agreement with the University of Missouri-Columbia Research Reactor Center (MURR), under which MURR will manufacture and supply to NeoRx the radioisotope holmium-166 for NeoRx's phase III clinical trial of STR (skeletal targeted radiotherapy).
Financial terms of the agreement were not disclosed.
NeoRx uses holmium-166 in the formulation of STR, its lead cancer-therapeutic candidate, at its radiopharmaceutical manufacturing facility in Denton, Texas. The company expects to announce in the next few weeks that it has opened ...